Grieg Seafood Asa Ord (GRGSF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

And welcome to ADAPT Immune's first quarter 2025 Business Update conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star, then 1 on your telephone keypad. Should you need assistance during the conference call, you may signal the operator by pressing star, then 0. I will now turn the call over to Julie Miller of Investor Relations for Adaptimmune. Julie, please go ahead. Thank you. Good morning, and welcome to Adaptimmune's conference call to discuss our first quarter 2025 business update. I would ask you to review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call, and actual results could differ materially due to several factors. including those outlined in our latest filings with the SEC. Adrian Rockliffe, our Chief Executive Officer, is here with me for the prepared portion of the call, and other members of our leadership team will be available for Q&A. With that, I'll turn the call over to Adrian Rockliffe. Thanks, Julie, and thank you, everybody, for joining us today. We now have one full quarter of T-cellular sales under our belt. and I'm delighted to be able to share with you the momentum that we're seeing with this launch. With 21 patients A4E so far in 2025, 13 in Q1, and another eight in the first part of Q2, we now feel confident sharing revenue guidance for the full year of between $35 million and $45 million in T-cellular sales. We believe this is attainable based on the number of patients we've seen through the treatment cycle, as well as the number of authorised treatment centres that we have up and ru...